Last updated: April 3, 2026
What is NDC 16714-0849?
NDC 16714-0849 pertains to Xywav, a synthetic oxybate formulation approved by the FDA in December 2021 for the treatment of narcolepsy, idiopathic hypersomnia, and cataplexy. It is marketed by Jazz Pharmaceuticals. Xywav is a low-sodium alternative to Xyrem (sodium oxybate).
Market Size and Demand
Current Utilization
- As of 2023, Xywav’s estimated prescriptions in the U.S. stand at approximately 20,000 units/month [1].
- The narcolepsy market in the U.S. is projected to reach $600 million by 2027, with a compound annual growth rate (CAGR) of around 7% [2].
- Indications such as idiopathic hypersomnia and cataplexy add incremental demand.
Competitive Landscape
- Xyrem dominates the oxybate market, with Xywav capturing roughly 25-30% of oxybate prescriptions since launch [3].
- Reduced sodium content positions Xywav favorably for patients with cardiovascular risk factors.
- Consider a market share shift as prescriber familiarity increases.
Pricing Structure and Revenue Projections
Current Pricing
- The average wholesale price (AWP) of Xywav is approximately $55 per gram [4].
- Typical prescription regimens involve 4.5 grams nightly, costing roughly $247/month per patient.
- Insurance coverage and discounts may reduce out-of-pocket costs.
Revenue Estimation
Depending on market penetration, the following revenue projections are outlined:
| Year |
Estimated Patients |
Market Share |
Monthly Revenue |
Annual Revenue |
| 2023 |
20,000 |
10% |
$4.4 million |
$52.8 million |
| 2024 |
25,000 |
15% |
$6.6 million |
$79.2 million |
| 2025 |
35,000 |
25% |
$11 million |
$132 million |
| 2026 |
45,000 |
35% |
$15.4 million |
$184.8 million |
Assumptions: steady increase in prescriptions, market share growth based on prescriber acceptance.
Price Projection Drivers
Regulatory and Market Dynamics
- Expansion into international markets may influence pricing strategies.
- Regulatory pressure to reduce costs can impact wholesale prices.
- The launch of biosimilar or generic oxybate formulations could pressure prices downward.
Economic Factors
- Inflation, supply chain costs, and healthcare reimbursement policies influence drug pricing.
- Negotiations with payers could lead to discounts and formulary placements affecting net revenue.
Competitive Strategies
- Price adjustments to maintain market share against Xyrem and potential generics.
- Value-based pricing models linked to clinical outcomes.
Risks and Opportunities
Risks
- Entry of biosimilars or generics may erode market share and pricing power.
- Changes in regulatory policies or reimbursement criteria.
- Slow prescriber adoption due to familiarity with existing therapies.
Opportunities
- Increasing diagnosis rates of narcolepsy and hypersomnia.
- Growing awareness and patient demand for low-sodium formulations.
- Potential expansion into new indications or geographic markets.
Key Takeaways
- Xywav (NDC 16714-0849) has an initial moderate market presence but potential for significant growth.
- Monthly revenue for the drug could reach approximately $15 million by 2026 with increased adoption.
- Price projections depend heavily on prescriber acceptance, competitive pressures, and healthcare policy environments.
- Strategic pricing and market expansion efforts will influence long-term revenue outcomes.
Frequently Asked Questions
1. How does Xywav compare price-wise to Xyrem?
Xywav’s wholesale price is about 20% lower per gram, driven by its lower sodium content, but actual retail costs depend on insurance negotiations.
2. What factors could decrease Xywav’s market share?
Emergence of biosimilar oxybate products, payer restrictions, or increased prescribing of alternative therapies.
3. Is there international market potential for Xywav?
Yes. Approval processes are underway in Europe and Asia, where demand for narcolepsy treatments exists, potentially expanding revenue streams.
4. How does patient cost influence prescribing patterns?
Insurance coverage and copay assistance programs significantly impact patient out-of-pocket costs, influencing prescription adherence.
5. What are the main risks affecting future price stability?
Market entry of generics, regulatory modifications, and payer negotiations are primary risks to price stability.
References
[1] IQVIA. (2023). Prescription Data for Xywav.
[2] Herbal, D. (2022). U.S. narcolepsy market forecast. MarketWatch.
[3] Jazz Pharmaceuticals. (2021). Xywav Launch Reports.
[4] Red Book. (2023). Wholesale drug prices.
